Tenaya Therapeutics Newsroom

LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsNov 25 15:31 ET · Ratings

H.C. Wainwright Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $18

Moomoo NewsNov 25 12:31 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target

BenzingaNov 25 11:56 ET

Positive Outlook for Tenaya Therapeutics: Strong Potential in Gene Therapy for Cardiovascular Diseases Supports Buy Rating

TipRanksNov 25 11:55 ET · Ratings

Tenaya Therapeutics Shares Are Trading Higher After the Company Announced It Dosed Its First Patient With TN-401 Gene Therapy in the RIDGE-1 Phase 1b Clinical Trial at the University of California, San Francisco.

BenzingaNov 25 11:11 ET

Express News | Tenaya Therapeutics Inc - Initial Clinical Data for Ridge-1 Expected in 2025

ReutersNov 25 08:30 ET

Express News | Tenaya Therapeutics Doses First Patient in Ridge™-1 Phase 1B Clinical Trial of Tn-401 for the Treatment of Pkp2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

ReutersNov 25 08:30 ET

Tenaya Therapeutics Reports Q3 2024 Progress and Financial Results

TipRanksNov 21 22:55 ET

Tenaya Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswireNov 19 08:00 ET

Express News | Tenaya Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

ReutersNov 19 08:00 ET

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Bolt Biotherapeutics (BOLT) and Amarin (AMRN)

TipRanksNov 19 02:00 ET · Ratings

Institutional Investors Have a Lot Riding on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) With 43% Ownership

Simply Wall StNov 10 07:33 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

BenzingaNov 8 16:06 ET

Tenaya Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesNov 7 09:26 ET · Ratings

Tenaya Therapeutics Analyst Ratings

BenzingaNov 7 09:14 ET · Ratings

A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $15 to $19

Moomoo NewsNov 7 08:00 ET · Ratings

Express News | Tenaya Therapeutics Inc : Chardan Capital Markets Cuts Target Price to $18 From $20

ReutersNov 6 22:25 ET

Buy Rating Affirmed for Tenaya Therapeutics Amid Positive DSMB Update and Strong Financial Position

TipRanksNov 6 21:45 ET · Ratings

Promising Developments and Safety Enhancements Bolster Buy Rating for Tenaya Therapeutics' Gene Therapy

TipRanksNov 6 19:15 ET · Ratings

Tenaya Therapeutics Reports Q3 EPS (30c), Consensus (37c)

TipRanksNov 6 17:08 ET